Abbott Laboratories (ABT) Financials
ABT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 73.2 billion | 34.4 billion |
2023-09-30 | 72.1 billion | 34.4 billion |
2023-06-30 | 73.4 billion | 36.0 billion |
2023-03-31 | 73.8 billion | 36.6 billion |
ABT Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 2.3 billion | 114.0 million |
2023-09-30 | 1.3 billion | 117.0 million |
2023-06-30 | 696.0 million | 132.0 million |
2023-03-31 | 763.0 million | 281.0 million |
ABT Net Income
Date | Net Income |
---|---|
2023-12-31 | 1.6 billion |
2023-09-30 | 1.4 billion |
2023-06-30 | 1.4 billion |
2023-03-31 | 1.3 billion |
ABT Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 7.3 billion | - | 949.0 million |
2023-09-30 | 7.0 billion | 14.5 billion | - |
2023-06-30 | 8.2 billion | 14.6 billion | - |
2023-03-31 | 10.2 billion | 14.6 billion | - |
ABT Shares Outstanding
ABT Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 755.0 million | 690.0 million | 2.7 billion | - |
2023-09-30 | 560.0 million | 672.0 million | 2.7 billion | - |
2023-06-30 | 507.0 million | 715.0 million | 2.7 billion | - |
2023-03-31 | 380.0 million | 654.0 million | 2.8 billion | - |
ABT Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 10.2 billion | 5.0 billion |
2023-09-30 | 10.1 billion | 4.6 billion |
2023-06-30 | 10.0 billion | 4.5 billion |
2023-03-31 | 9.7 billion | 4.3 billion |
ABT
List: Contenders
Price: 113.66USD
Dividend Yield: 1.85%
Forward Dividend Yield: 1.94%
Payout Ratio: 67.48%
Dividend Per Share: 2.20 USD
Earnings Per Share: 3.26 USD
P/E Ratio: 34.97
Exchange: NYQ
Sector: Healthcare
Industry: Medical Devices
Volume: 5.1 million
Ebitda: 1.7 billionMarket Capitalization: 205.8 billion
Average Dividend Frequency: 4
Years Paying Dividends: 42
DGR3: 10.70%
DGR5: 11.14%
DGR10: 11.53%
DGR20: 7.48%